Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All aspirin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19

Liu et al., Medicine, doi:10.1097/MD.0000000000024544
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
0 0.5 1 1.5 2+ Mortality 75% Improvement Relative Risk Mortality (b) 81% Time to viral- -2% Aspirin for COVID-19  Liu et al.  LATE TREATMENT Is late treatment with aspirin beneficial for COVID-19? PSM retrospective 232 patients in China Lower mortality with aspirin (p=0.03) c19early.org Liu et al., Medicine, February 2021 Favors aspirin Favors control
Aspirin for COVID-19
24th treatment shown to reduce risk in August 2021
 
*, now known with p = 0.000087 from 73 studies, recognized in 3 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective PSM analysis of 232 hospitalized patients, 28 treated with aspirin, showing lower mortality with treatment. There was no significant difference in viral clearance.
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter et al. show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
risk of death, 75.0% lower, HR 0.25, p = 0.03, treatment 2 of 28 (7.1%), control 11 of 204 (5.4%), adjusted per study, 60 days, KM, PSM.
risk of death, 81.0% lower, HR 0.19, p = 0.02, treatment 1 of 28 (3.6%), control 9 of 204 (4.4%), adjusted per study, 30 days, KM, PSM.
time to viral-, 1.9% higher, relative time 1.02, p = 0.94, treatment 24, control 24, PSM.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Liu et al., 12 Feb 2021, retrospective, propensity score matching, China, peer-reviewed, 8 authors.
This PaperAspirinAll
{ 'indexed': {'date-parts': [[2024, 3, 24]], 'date-time': '2024-03-24T07:33:14Z', 'timestamp': 1711265594275}, 'reference-count': 10, 'publisher': 'Ovid Technologies (Wolters Kluwer Health)', 'issue': '6', 'license': [ { 'start': { 'date-parts': [[2021, 2, 12]], 'date-time': '2021-02-12T00:00:00Z', 'timestamp': 1613088000000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0'}], 'funder': [ { 'DOI': '10.13039/501100001809', 'name': 'National Nature Science Foundation of China', 'doi-asserted-by': 'crossref', 'award': ['81402404']}, { 'DOI': '10.13039/501100001809', 'name': 'National Nature Science Foundation of China', 'doi-asserted-by': 'crossref', 'award': ['81402404']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:sec>\n' ' <jats:title>Abstract</jats:title>\n' ' <jats:p>To clarify the effect of aspirin on mortality and viral duration in ' 'adults infected with respiratory syndrome coronavirus 2 (SARS-Cov-2).</jats:p>\n' ' <jats:p>After propensity score-matched (PSM) case-control analyses 24 pairs of ' 'patients were enrolled and followed up for 2\u200amonths. Both 30-day and 60-day mortality in ' 'the aspirin group were significantly lower than that in the non-aspirin group (<jats:italic ' 'toggle="yes">P</jats:italic>\u200a=\u200a.021 and <jats:italic ' 'toggle="yes">P</jats:italic>\u200a=\u200a.030, respectively). The viral duration time between ' 'the 2 groups was not significantly different (<jats:italic toggle="yes">P</jats:italic>\u200a' '=\u200a.942).</jats:p>\n' ' <jats:p>Among adults (with hypertension, cardiovascular diseases) infected with ' 'SARS-Cov-2, low-dose aspirin medication (100\u200amg/day) was associated with lower risk of ' 'mortality compared with non-aspirin users.</jats:p>\n' ' </jats:sec>', 'DOI': '10.1097/md.0000000000024544', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 22]], 'date-time': '2021-02-22T16:34:17Z', 'timestamp': 1614011657000}, 'page': 'e24544', 'source': 'Crossref', 'is-referenced-by-count': 28, 'title': 'Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with ' 'COVID-19', 'prefix': '10.1097', 'volume': '100', 'author': [ { 'given': 'Qiang', 'family': 'Liu', 'sequence': 'first', 'affiliation': [ { 'name': "Department of Infectious Disease, Yichang Central People's " 'Hospital, The First College of Clinical Medical Science, China ' 'Three Gorges University, Yichang'}]}, { 'given': 'Na', 'family': 'Huang', 'sequence': 'additional', 'affiliation': [ { 'name': "Department of Infectious Disease, Yichang Central People's " 'Hospital, The First College of Clinical Medical Science, China ' 'Three Gorges University, Yichang'}]}, { 'given': 'Anni', 'family': 'Li', 'sequence': 'additional', 'affiliation': [ { 'name': "Department of Infectious Disease, Yichang Central People's " 'Hospital, The First College of Clinical Medical Science, China ' 'Three Gorges University, Yichang'}]}, { 'given': 'Yuanhong', 'family': 'Zhou', 'sequence': 'additional', 'affiliation': [ { 'name': "Department of Infectious Disease, Yichang Central People's " 'Hospital, The First College of Clinical Medical Science, China ' 'Three Gorges University, Yichang'}]}, { 'given': 'Liang', 'family': 'Liang', 'sequence': 'additional', 'affiliation': [ { 'name': "Department of Infectious Disease, Yichang Central People's " 'Hospital, The First College of Clinical Medical Science, China ' 'Three Gorges University, Yichang'}]}, { 'given': 'Xinyu', 'family': 'Song', 'sequence': 'additional', 'affiliation': [ { 'name': "Department of Infectious Disease, Yichang Central People's " 'Hospital, The First College of Clinical Medical Science, China ' 'Three Gorges University, Yichang'}]}, { 'given': 'Zhanqiu', 'family': 'Yang', 'sequence': 'additional', 'affiliation': [ { 'name': 'State Key Laboratory of Virology, Institute of Medical Virology, ' 'School of Medicine, Wuhan University, Wuhan, Hubei, China.'}]}, { 'ORCID': 'http://orcid.org/0000-0002-9437-9896', 'authenticated-orcid': False, 'given': 'Xiaolin', 'family': 'Zhou', 'sequence': 'additional', 'affiliation': [ { 'name': "Department of Infectious Disease, Yichang Central People's " 'Hospital, The First College of Clinical Medical Science, China ' 'Three Gorges University, Yichang'}]}], 'member': '276', 'published-online': {'date-parts': [[2021, 2, 12]]}, 'reference': [ { 'key': 'R1-20230916', 'doi-asserted-by': 'crossref', 'first-page': '568', 'DOI': '10.1002/jmv.25748', 'article-title': 'Unique epidemiological and clinical features of the emerging 2019 novel ' 'coronavirus pneumonia (COVID-19) implicate special control measures', 'volume': '92', 'author': 'Wang', 'year': '2020', 'journal-title': 'J Med Virol'}, { 'key': 'R2-20230916', 'first-page': '1023', 'article-title': 'COVID-19 and treatment with NSAIDs and corticosteroids: should we be ' 'limiting their use in the clinical setting?', 'volume': '14', 'author': 'Russell', 'year': '2020', 'journal-title': 'E cancer medical science'}, { 'key': 'R3-20230916', 'doi-asserted-by': 'crossref', 'first-page': '252', 'DOI': '10.1177/1534735406291499', 'article-title': 'Preadministration of high-dose salicylates, suppressors of NF-kappaB ' 'activation, may increase the chemosensitivity of many cancers: an ' 'example of proapoptotic signal modulation therapy', 'volume': '5', 'author': 'McCarty', 'year': '2006', 'journal-title': 'Integrity Cancer Therapy'}, { 'key': 'R4-20230916', 'doi-asserted-by': 'crossref', 'first-page': '1462', 'DOI': '10.1002/hep.22215', 'article-title': 'Acetylsalicylic acid inhibits hepatitis C virus RNA and protein ' 'expression through cyclooxygenase 2 signalling pathways', 'volume': '47', 'author': 'Trujillo', 'year': '2008', 'journal-title': 'Hepatology'}, { 'key': 'R5-20230916', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/jmv.25884', 'article-title': 'Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis', 'author': 'Zhu', 'year': '2020', 'journal-title': 'J Med Virol'}, { 'key': 'R6-20230916', 'doi-asserted-by': 'crossref', 'first-page': '19', 'DOI': '10.3121/cmr.2007.698', 'article-title': 'An evidence-based update on nonsteroidal anti-inflammatory drugs', 'volume': '5', 'author': 'Ong', 'year': '2007', 'journal-title': 'Clin Med Res'}, { 'key': 'R7-20230916', 'article-title': 'Goodman and Gilmans the Pharmacological Basis of Therapeutics', 'year': '2006'}, { 'key': 'R8-20230916', 'doi-asserted-by': 'crossref', 'first-page': 'm1409', 'DOI': '10.1136/bmj.m1409', 'article-title': 'Covid-19: NICE advises against using NSAIDs for fever in patients with ' 'suspected cases', 'volume': '369', 'author': 'Torjesen', 'year': '2020', 'journal-title': 'BMJ'}, { 'key': 'R9-20230916', 'doi-asserted-by': 'crossref', 'first-page': '85', 'DOI': '10.1111/irv.12421', 'article-title': 'Antiviral activity of aspirin against RNA viruses of the respiratory ' 'tract-an in vitro study', 'volume': '11', 'author': 'Glatthaar-Saalmüller', 'year': '2017', 'journal-title': 'Influenza Other Respir Viruses'}, { 'key': 'R10-20230916', 'first-page': '51', 'article-title': 'Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after ' 'intravenous and oral administration to healthy volunteers', 'volume': '6', 'author': 'Nagelschmitz', 'year': '2014', 'journal-title': 'Clin Pharmacol'}], 'container-title': 'Medicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://journals.lww.com/10.1097/MD.0000000000024544', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 9, 16]], 'date-time': '2023-09-16T03:08:29Z', 'timestamp': 1694833709000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journals.lww.com/10.1097/MD.0000000000024544'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 2, 12]]}, 'references-count': 10, 'journal-issue': {'issue': '6', 'published-online': {'date-parts': [[2021]]}}, 'URL': 'http://dx.doi.org/10.1097/MD.0000000000024544', 'relation': {}, 'ISSN': ['0025-7974', '1536-5964'], 'subject': ['General Medicine'], 'published': {'date-parts': [[2021, 2, 12]]}}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit